Advocates, Researchers Oppose Pharma Executive’s Plan To Raise Price Of Chagas Drug; Plan Raises Questions About FDA Voucher System For Neglected Diseases
The Independent: Martin Shkreli: The ‘most hated man in America’ is raising the price of another form of drug
“The man who increased the cost of an effective [toxoplasmosis] drug by 5,500 percent has now increased the price of another form of medicine. Martin Shkreli has now increased the price of a medicine used to treat Chagas disease, a parasitic infection that can cause heart failure…” (Grice, 12/12).
International Business Times: Martin Shkreli, Pharma’s Most Notorious Exec, Denies Move On Parasitic Disease Treatment Is To Game FDA Voucher System
“…Shkreli said he’s applied to obtain a so-called priority-review voucher from the U.S. Food and Drug Administration (FDA) that could speed the agency’s approval of benznidazole, which is used to treat Chagas. The issue raises questions about how the U.S. government promotes drug development and whether this is part of a larger problem that causes patients and their insurers to pay so much money for so many drugs. These FDA vouchers can be worth hundreds of millions of dollars when they’re acquired by one company and sold to another firm…” (Young, 12/12).
New York Times: Martin Shkreli’s Latest Plan to Sharply Raise Drug Price Prompts Outcry
“…Mr. Shkreli said on a conference call with KaloBios investors last week that if the company won FDA approval for benznidazole, it would have exclusive rights to sell it in the United States for at least five years. He said the price would be similar to that of hepatitis C drugs, which cost $60,000 to nearly $100,000 for a course of treatment. In Latin America, benznidazole costs $50 to $100 for the typical two-month course of treatment…” (Pollack, 12/11).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.